Ektoras Xanthias Georgiou

Ektoras Xanthias Georgiou

Auto-generated profile, based on publicly available information

Ektoras Xanthias Georgiou

Reproductive Services Unit, The Royal Women's Hospital, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
JCJennifer E. Cole
Jennifer E. Cole
EGEktoras Georgiou
Ektoras Georgiou
CMClaudia Monaco
Claudia Monaco
Inflammation drives atherosclerosis. Both immune and resident vascular cell types are involved in the development of atherosclerotic lesions. The phenotype and function of these cells are key in determining the development of lesions. Toll-like receptors are the most characterised innate immune receptors and are responsible for the recognition of exogenous conserved motifs on pathogens, and, potentially, some endogenous molecules. Both endogenous and exogenous TLR agonists may be present in atherosclerotic plaques. Engagement of toll-like receptors on immune and resident vascular cells can affect atherogenesis as signalling downstream of these receptors can elicit proinflammatory cytokine release, lipid uptake, and foam cell formation and activate cells of the adaptive immune system. In this paper, we will describe the expression of TLRs on immune and resident vascular cells, highlight the TLR ligands that may act through TLRs on these cells, and discuss the consequences of TLR activation in atherosclerosis.

6 July 2011 in BMJ
Verified
Journal Article
Closed access
PDF file
SSSrdjan Saso
Srdjan Saso
JCJayanta Chatterjee
Jayanta Chatterjee
EGEktoras Georgiou
Ektoras Georgiou
ADAnthony M Ditri
Anthony M Ditri
JSJ Richard Smith
J Richard Smith
SGSadaf Ghaem-Maghami
Sadaf Ghaem-Maghami

20 November 2019 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
EGEktoras X Georgiou
Ektoras X Georgiou
PMPedro Melo
Pedro Melo
PBPhilip E Baker
Philip E Baker
HSHassan N Sallam
Hassan N Sallam
AAAydin Arici
Aydin Arici
IGIngrid E Granne
Ingrid E Granne

17 September 2018 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Closed access
PDF file
PMPedro Melo
Pedro Melo
EGEktoras Xanthias Georgiou
Ektoras Xanthias Georgiou
AHAnita Hedditch
Anita Hedditch
PEPauline Ellaway
Pauline Ellaway
LILawrence Impey
Lawrence Impey

28 November 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KLKaiyu Lei
Kaiyu Lei
LCLi Chen
Li Chen
EGEktoras X. Georgiou
Ektoras X. Georgiou
SSSuren R. Sooranna
Suren R. Sooranna
SKShirin Khanjani
Shirin Khanjani
MJMark R Johnson
Mark R Johnson
Progesterone is widely used to prolong gestation in women at risk of preterm labour (PTL), and acts at least in part via the inhibition of inflammatory cytokine-induced prostaglandin synthesis. This study investigates the mechanisms responsible for this inhibition in human myometrial cells. We used reporter constructs to demonstrate that interleukin 1beta (IL-1β) inhibits progesterone driven PRE activation via p65 activation and that IL-1β reduced progesterone driven gene expression (FKBP5). Conversely, we found that the activity of a p65-driven NFκB reporter construct was reduced by overexpression of progesterone receptor B (PRB) alone and that this was enhanced by the addition of MPA and that both MPA and progesterone suppressed IL-1β-driven cyclo-oxygenase-2 (COX-2) expression. We found that over-expressed Halo-tagged PRB, but not PRA, bound to p65 and that in IL-1β-treated cells, with no overexpression of either PR or p65, activated p65 bound to PR. However, we found that the ability of MPA to repress IL-1β-driven COX-2 expression was not enhanced by overexpression of either PRB or PRA and that although the combined PR and GR antagonist Ru486 blocked the effects of progesterone and MPA, the specific PR antagonist, Org31710, did not, suggesting that progesterone and MPA act via GR and not PR. Knockdown using siRNA confirmed that both MPA and progesterone acted via GR and not PR or AR to repress IL-1β-driven COX-2 expression. We conclude that progesterone acts via GR to repress IL-1β-driven COX-2 activation and that although the interaction between p65 and PRB may be involved in the repression of progesterone driven gene expression it does not seem to be responsible for progesterone repression of IL-1β-induced COX-2 expression.

1 October 2015 in Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
KLK. Lei
K. Lei
EGE. X. Georgiou
E. X. Georgiou
LCL. Chen
L. Chen
AYA. Yulia
A. Yulia
SSS. R. Sooranna
S. R. Sooranna
MJMark R Johnson
Mark R Johnson
Progesterone (P4) maintains uterine quiescence during pregnancy and its functional withdrawal is associated with increased prostaglandin synthesis and the onset of labor. In primary human myometrial cells, the glucocorticoid receptor (GR) rather than the P4 receptor mediates P4 antagonism of IL-1β-induced cyclooxygenase-2 (COX-2) expression, the rate-limiting enzyme in prostaglandin synthesis. We now report that P4 also acts via GR to induce MAPK phosphatase (MKP)-1 and knockdown of MKP-1 impairs the ability of P4 to repress IL-1β-dependent COX-2 induction. Microarray analysis revealed that P4 repressed preferentially activator protein-1-responsive genes in response to IL-1β. Consistent with these observations, we found that the ability of P4 to reduce c-Jun activation was lost upon GR as well as MKP-1 knockdown. Interestingly, c-Jun levels in human myometrial cells declined upon GR and MKP-1 knockdown, which suggests the presence of an activator protein-1 feedback loop. This is supported by our observation that c-Jun levels declined after an initial rise in primary myometrial cells treated with phorbol 12-myrisatate 13-acetate, a potent activator of c-Jun N-terminal kinase. Finally, we show that MKP-1 is an intermediate in P4-mediated repression of some but not all IL-1β-responsive genes. For example, P4 repression of IL11 and IRAK3 was maintained upon MKP-1 knockdown. Taken together, the data show that P4 acts via GR to drive MKP-1 expression, which in turn inhibits IL-1β-dependent c-Jun activation and COX-2 expression.